Topical chlormethine (CL) gel formulation was approved by the EMA in 2017 for the treatment of adult patients with mycosis fungoides (MF). To expand the knowledge on the management of MF, this paper provides an overview of clinical practice evidence about the MF diagnostic phase and a collection of clinical experiences to better characterize the use of CL gel in daily practice. Collected cases underline the importance of the concomitant biopsy and clinical evaluation in the diagnostic phase, with the contribution of a multidisciplinary team, and support the use of CL gel as a first-line or adjuvant treatment in selected patients.

Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences / S. Alberti Violetti, M. Ardigò, P. Fava, G. Gritti, E. Morsia, F. Onida, M. Paulli, A. Pileri, P. Quaglino, S. Rupoli, M. Teoli, P. Vezzoli. - In: DRUGS IN CONTEXT. - ISSN 1740-4398. - 13:(2024), pp. 202461.1-202461.12. [10.7573/dic.2024-6-1]

Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences

S. Alberti Violetti
Primo
;
G. Gritti;F. Onida;P. Vezzoli
Ultimo
2024

Abstract

Topical chlormethine (CL) gel formulation was approved by the EMA in 2017 for the treatment of adult patients with mycosis fungoides (MF). To expand the knowledge on the management of MF, this paper provides an overview of clinical practice evidence about the MF diagnostic phase and a collection of clinical experiences to better characterize the use of CL gel in daily practice. Collected cases underline the importance of the concomitant biopsy and clinical evaluation in the diagnostic phase, with the contribution of a multidisciplinary team, and support the use of CL gel as a first-line or adjuvant treatment in selected patients.
chlormethine gel; cutaneous T cell lymphoma; mycosis fungoides
Settore MEDS-09/B - Malattie del sangue
Settore MEDS-10/C - Malattie cutanee e veneree
Settore MEDS-09/A - Oncologia medica
2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
unpaywall-bitstream--876743721.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Licenza: Creative commons
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1169953
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
  • OpenAlex ND
social impact